Skip to main content
. Author manuscript; available in PMC: 2010 May 3.
Published in final edited form as: Exp Dermatol. 2009 Jun;18(6):548–552. doi: 10.1111/j.1600-0625.2008.00827.x

Table 1.

Analysis of the San Francisco Bay Area cohort independently of ethnicity and BRAF mutation status.

Tumors Papillary thyroid carcinoma Follicular thyroid carcinoma
Cases Controls OR
(95% CI)		 Cases Controls OR
(95% CI)
MC1R
consensus		 12 20 reference 13 10 reference
1 MC1R
variant		 26 16 2.708
(1.049 to
6.994)		 29 26 0.858
(0.322 to
2.286)
≥ 2 MC1R
variants		 24 26 1.539
(0.622 to
3.805)		 24 30 0.615
(0.230 to
1.646)
total 62 62 p = 0.108* 66 66 p = 0.543*

Given are odds ratios for papillary (PTC) and follicular (FTC) thyroid carcinoma depending on the number of MC1R variants compared to the matched control cohort.

*

Pearson chi-square test.